glp-1 drugs and alzheimer's 🧐Will GLP-1RA be the future of altzeimers treatement? 🧠There are multiple studies underway assessing the effectiveness of class of medications in prevention and/or delay of dementia 🧠Alzheimer's makes up 60%-80% GLP-1 Agonists: Obesity & Alzheimer's

Why this timing matters: This is exactly why doctors recommend that 2-3 month washout period

Why Fatty Liver Disease Is a Metabolic Health Warning Sign Fatty liver disease often reflects broader metabolic stress

Nearly four in ten (37%) adults ages 65 and older report being told by a doctor they are overweight or obese in the past five years

[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ

Purpose-built for physicians GLP-1, SGLT2 combination therapy provides largest weight loss for women with PCOS Combination therapy with a GLP-1 receptor agonist and an SGLT2 inhibitor may provide better weight-loss benefits than a single agent for women with polycystic ovary syndrome and obesity, according to study data